Abstract
Influenza remains an important cause of morbidity and mortality, and incurs substantial economic costs (mainly due to hospitalisation) especially for the elderly aged 65 years or more, and among those with high-risk medical conditions. Influenza vaccination is the most effective control measure for both healthy populations and the chronically ill in whom complications of influenza cluster. Unfortunately, vaccination is less effective in the elderly and immunocompromised persons. Additional benefit may accrue from other health care interventions including antiviral therapy. Oseltamivir, a neuraminidase inhibitor, has become a drug of public health importance since it was included in influenza pandemic management plans. Many systematic reviews and meta-analyses of oseltamivir treatment and prophylaxis trials have been published. We provide a summary of the conclusions and review the various findings of economic analyses. Future randomised controlled trials should focus upon costly outcomes such as hospital admissions and should be conducted in populations at high risk of complications from influenza. Future economic analyses need to address variation in (1) willing-to-pay value, (2) annual attack rate of influenza, and (3) influenza vaccination effectiveness and uptake rates.
Keywords: Adolescents, adults, clinical impact, economic review, influenza, oseltamivir.
Infectious Disorders - Drug Targets
Title:Oseltamivir Use in Adolescents and Adults: Clinical and Economic Considerations
Volume: 13 Issue: 1
Author(s): J. Kevin Yin, Leon Heron, Glenn Salkeld, Harunor Rashid and Robert Booy
Affiliation:
Keywords: Adolescents, adults, clinical impact, economic review, influenza, oseltamivir.
Abstract: Influenza remains an important cause of morbidity and mortality, and incurs substantial economic costs (mainly due to hospitalisation) especially for the elderly aged 65 years or more, and among those with high-risk medical conditions. Influenza vaccination is the most effective control measure for both healthy populations and the chronically ill in whom complications of influenza cluster. Unfortunately, vaccination is less effective in the elderly and immunocompromised persons. Additional benefit may accrue from other health care interventions including antiviral therapy. Oseltamivir, a neuraminidase inhibitor, has become a drug of public health importance since it was included in influenza pandemic management plans. Many systematic reviews and meta-analyses of oseltamivir treatment and prophylaxis trials have been published. We provide a summary of the conclusions and review the various findings of economic analyses. Future randomised controlled trials should focus upon costly outcomes such as hospital admissions and should be conducted in populations at high risk of complications from influenza. Future economic analyses need to address variation in (1) willing-to-pay value, (2) annual attack rate of influenza, and (3) influenza vaccination effectiveness and uptake rates.
Export Options
About this article
Cite this article as:
Yin Kevin J., Heron Leon, Salkeld Glenn, Rashid Harunor and Booy Robert, Oseltamivir Use in Adolescents and Adults: Clinical and Economic Considerations, Infectious Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/18715265112129990008
DOI https://dx.doi.org/10.2174/18715265112129990008 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Peptide Radiopharmaceuticals in the Imaging of Acute Thrombus
Current Pharmaceutical Design The Role of Matrix Gla Protein (MGP) in Vascular Calcification
Current Medicinal Chemistry Pneumonia Caused by Staphylococcus aureus
Current Respiratory Medicine Reviews An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents Editorial from Editor-in-Chief (SCUBA Diving and Changes in Lung Function: Where is the Data?)
Current Respiratory Medicine Reviews Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists
Current Drug Targets Up-Regulation of Gr1+CD11b+ Population in Spleen of Dextran Sulfate Sodium Administered Mice Works to Repair Colitis
Inflammation & Allergy - Drug Targets (Discontinued) Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences
Current Drug Delivery Challenges in the Management of Severe Asthma: Role of Current and Future Therapies
Current Pharmaceutical Design DNA Polymerases and Oxidative Damage: Friends or Foes?
Current Molecular Pharmacology Activin-A: A New Piece in the Puzzle of Tolerance in Asthma
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Use of Antibiotics in Bronchiectasis
Reviews on Recent Clinical Trials Adolescent Asthma Management
Current Pediatric Reviews Studies on the Pathophysiology and Genetic Basis of Migraine
Current Genomics Strategies to Optimize the Effectiveness of Antifungal Treatment for Invasive Aspergillosis
Anti-Infective Agents Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Novel Antimicrobial Agents for the Management of Maxillofacial and Neck Infections
Recent Patents on Anti-Infective Drug Discovery Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine
Current Medicinal Chemistry Clinical Experience with Specific COX-2 Inhibitors in Arthritis
Current Pharmaceutical Design Oxidative Brain Damage by Peroxynitrite in Bacterial Meningitis: A Target for Adjunctive Therapy?
Current Medicinal Chemistry - Central Nervous System Agents